Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting

MALVERN, Penn. — October 23, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from its Phase 2b clinical trial evaluating avasopasem manganese (GC4419), a highly selective and potent small molecule dismutase mimetic, in patients with … Continued

Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)

Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application

MALVERN, Penn. — October 15, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced the first patient has been dosed in a Phase 3 clinical trial of avasopasem manganese (GC4419) to reduce the incidence and severity … Continued

Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication

Pivotal trial of GC4419 for the treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018

MALVERN, Penn. — September 19, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced it has secured $150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new … Continued

Galera Therapeutics Presents Structure and Synthesis of GC4419 at American Chemical Society Annual Meeting

Presentation selected as part of The Halpern Legacy Symposium and press program

Phase 3 trial of GC4419 for treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018

MALVERN, Penn. — Aug. 20, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced that Co-Founder and Chief Scientific Officer Dennis Riley, Ph.D., will deliver an oral presentation as part of The Halpern Legacy Symposium today at … Continued

Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual Meeting

GC4419 demonstrated clinically significant reduction in duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer

Trial investigator Dr. Carryn Anderson honored with Steven M. Grunberg Memorial Award for excellence in cancer research

MALVERN, Penn. — June 29, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from the Phase 2b clinical trial evaluating GC4419, a highly selective and potent small molecule dismutase mimetic, were presented today during an … Continued

Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at MASCC/ISOO 2018 Annual Meeting

Abstract receives Steven M. Grunberg Memorial Award for excellence in cancer research

MALVERN, Penn. — June 12, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced data from its Phase 2b clinical trial of lead product candidate GC4419 for the treatment of severe oral mucositis (SOM) in patients … Continued

Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419 Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

GC4419 met primary endpoint, achieving 92 percent reduction in duration of severe oral mucositis (SOM) in patients with head and neck cancer

GC4419 also demonstrated reduction in SOM incidence and severity, and was well tolerated

Abstract to be featured in 2018 Best of ASCO program

MALVERN, Penn. — June 3, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from the Phase 2b clinical trial evaluating GC4419, a highly selective and potent small molecule dismutase mimetic, were presented today during an … Continued

Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Data demonstrate GC4419 reduced duration, incidence and severity of radiation-induced severe oral mucositis in patients with head and neck cancer
Abstract selected for 2018 Best of ASCO program

MALVERN, Penn. — May 16, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced that data from its Phase 2b clinical trial of GC4419 for severe oral mucositis in patients with head and neck cancer will be presented during an … Continued

Galera Therapeutics Announces Preclinical Data Demonstrating Potential of GC4419 to Improve Effectiveness of Radiation While Preventing Normal Tissue Toxicity

Posters presented at 2018 American Association for Cancer Research Annual Meeting

  MALVERN, Penn. — Apr. 16, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced that preclinical data on GC4419, a highly selective and potent small molecule dismutase mimetic, were presented during poster sessions at the 2018 American Association for … Continued

Galera Therapeutics Announces Dosing of First Patient in Phase 1/2 Pancreatic Cancer Clinical Trial of GC4419

First Clinical Trial Evaluating Anti-Tumor Effect of GC4419 in Combination with Radiation

MALVERN, Penn. — Feb. 28, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company developing drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, today announced the first patient with locally advanced pancreatic cancer (LAPC) has been dosed in a Phase 1/2 clinical trial of lead candidate GC4419, a highly selective and … Continued